Label change history
Medically reviewed by Dr. Sofia Lindqvist, · Last reviewed 11 August 2026
Last verified 11 August 2026. Next scheduled verification 11 November 2026.
A chronology of significant labelling changes and safety communications for the drugs covered on this site. This page exists because label changes are the most reliable signal of what regulators have learned about a drug since approval, and because they are difficult to find scattered across regulator websites.
On this page
Modafinil: pregnancy and reproductive safety
| Date | Regulator | Action |
|---|---|---|
| April 2019 | EMA | Adopted labelling changes stating modafinil is suspected to cause congenital malformations when administered during pregnancy, and should not be used during pregnancy |
| June 2019 | Health Canada | Contraindicated Alertec in women who are pregnant or may become pregnant, citing association with major fetal congenital malformations including cardiac anomalies |
| June 2019 | Ireland (HPRA) | Labelling update and Dear Healthcare Professional letter |
| 2019 | Australia (TGA) | Contraindicated in pregnancy |
| January 2020 | UK | Direct Healthcare Professional Communication on potential risk of congenital malformations during pregnancy |
| November 2020 | MHRA | Drug Safety Update: should not be used in pregnancy; effective contraception required during treatment and for two months after stopping |
| Ongoing | FDA | Has not required equivalent contraindication labelling. Public Citizen filed a petition urging contraindication for modafinil and armodafinil. Current status UNVERIFIED |
Underlying evidence. The signal arose from the US Nuvigil and Provigil Pregnancy Registry together with spontaneous postmarketing reports. Malformation types reported include congenital heart defects, hypospadias and orofacial clefts. A European case series additionally suggested a dose dependent reduction in birth weight and head circumference, though clinical relevance remains uncertain.
US pregnancy registry
EMA review, 2019
National action
FDA
Modafinil: dermatological and hypersensitivity reactions
| Date | Regulator | Action |
|---|---|---|
| 2006 | FDA | Rejected paediatric application, in part due to a confirmed case of Stevens Johnson syndrome in clinical trials |
| UNVERIFIED | FDA | Labelling updated to include serious skin reactions including Stevens Johnson syndrome, toxic epidermal necrolysis and DRESS |
| UNVERIFIED | Multiple | Labelling changes addressing angioedema and anaphylactoid reactions |
Modafinil: patent and generic entry
| Date | Event |
|---|---|
| 1998 | FDA approves Provigil (Cephalon) |
| 2001 | Composition patent expires per court filings. One source gives 2010 UNVERIFIED against the Orange Book, for US 4,927,855 |
| 2005 to 2006 | Cephalon settles with Teva, Barr, Mylan and Ranbaxy, delaying generic entry to April 2012 |
| 2007 | FDA approves armodafinil (Nuvigil) |
| April 2012 | Generic modafinil enters the US market, per the settlement date rather than patent expiry |
| September 2012 | Generic approved by Orion Pharms |
| April 2015 | Reissue particle size patent would have expired |
| 2016 | Cephalon and Teva settle with 49 states and DC for $125 million over the pay for delay arrangements |
Solriamfetol and pitolisant
| Date | Drug | Event |
|---|---|---|
| 2019 | Solriamfetol | FDA approval for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea |
| 2019 | Pitolisant | FDA approval for cataplexy or excessive daytime sleepiness in narcolepsy |
| UNVERIFIED | Pitolisant | Paediatric indication added |
Change log
| Date | Change | Source |
|---|---|---|
| 11 August 2026 | Page created | EMA, MHRA, Health Canada, HPRA, TGA, FDA |
Why track label changes at all?
Do all regulators treat modafinil in pregnancy the same way?
What did the pregnancy registry find?
The UK 2020 communication reported that of 78 prospective pregnancy cases, 61 reported a live birth, of which 9 presented with major congenital anomalies.